These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38699313)

  • 1. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage.
    Lewnard JA; Mahale P; Malden D; Hong V; Ackerson BK; Lewin BJ; Link-Gelles R; Feldstein LR; Lipsitch M; Tartof SY
    medRxiv; 2024 Apr; ():. PubMed ID: 38699313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage.
    Lewnard JA; Mahale P; Malden D; Hong V; Ackerson BK; Lewin BJ; Link-Gelles R; Feldstein LR; Lipsitch M; Tartof SY
    Nat Commun; 2024 Oct; 15(1):8550. PubMed ID: 39362845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
    Lancet Infect Dis; 2024 Sep; 24(9):964-973. PubMed ID: 38761806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J
    Clin Infect Dis; 2024 Aug; ():. PubMed ID: 39107255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J
    medRxiv; 2024 Jun; ():. PubMed ID: 38883802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appearance and Prevalence of JN.1 SARS-CoV-2 Variant in India and Its Clinical Profile in the State of Maharashtra.
    Karyakarte RP; Das R; Rajmane MV; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Kulkarni PP; Nizarudeen S; Yanamandra S; Taji N; Joshi S; Potdar V
    Cureus; 2024 Mar; 16(3):e56718. PubMed ID: 38646375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
    Wang W; Bhushan G; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Pollett SD; Mitre E; Katzelnick LC; Weiss CD
    J Virol; 2024 Nov; 98(11):e0094824. PubMed ID: 39365051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.
    Lewnard JA; Hong V; Kim JS; Shaw SF; Lewin B; Takhar H; Lipsitch M; Tartof SY
    Nat Commun; 2023 Jun; 14(1):3854. PubMed ID: 37386005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome.
    Lewnard JA; Hong V; Kim JS; Shaw SF; Lewin B; Takhar H; Tartof SY
    Nat Commun; 2023 Mar; 14(1):1407. PubMed ID: 36918548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion.
    Li P; Liu Y; Faraone J; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu SL
    bioRxiv; 2024 Mar; ():. PubMed ID: 38559216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024.
    Link-Gelles R; Ciesla AA; Mak J; Miller JD; Silk BJ; Lambrou AS; Paden CR; Shirk P; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2024 Feb; 73(4):77-83. PubMed ID: 38300853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of SARS-CoV-2 JN.1 Infection and COVID-19-Associated Emergency Department Visits/Hospitalizations Following Updated Boosters and Prior Infection: A Population-Based Cohort Study.
    Chong C; Wee LE; Jin X; Zhang M; Malek MIA; Ong B; Lye D; Chiew CJ; Tan KB
    Clin Infect Dis; 2024 Nov; 79(5):1190-1196. PubMed ID: 38922669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024.
    de Prost N; Audureau E; Guillon A; Handala L; Préau S; Guigon A; Uhel F; Le Hingrat Q; Delamaire F; Grolhier C; Tamion F; Moisan A; Darreau C; Thomin J; Contou D; Henry A; Daix T; Hantz S; Saccheri C; Giordanengo V; Pham T; Chaghouri A; Bay P; Pawlotsky JM; Fourati S;
    Ann Intensive Care; 2024 Jun; 14(1):101. PubMed ID: 38940865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring New COVID-19 Incertitude: JN.1 Variant- JN.1: The Queer Bird among Omicron Sublineages.
    Ray SK; Mukherjee S
    Infect Disord Drug Targets; 2025; 25(1):e270624231369. PubMed ID: 38939989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant.
    Levy ME; Chilunda V; Davis RE; Heaton PR; Pawloski PA; Goldman JD; Schandl CA; McEwen LM; Cirulli ET; Wyman D; Rossi AD; Dai H; Isaksson M; Washington NL; Basler T; Tsan K; Nguyen J; Ramirez J; Sandoval E; Lee W; Lu J; Luo S
    J Infect Dis; 2024 Nov; 230(5):1197-1201. PubMed ID: 39028664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
    Sohail MS; Ahmed SF; Quadeer AA; McKay MR
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.